Mayne Pharma Group Ltd
ASX:MYX
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
AU |
Mayne Pharma Group Ltd
ASX:MYX
|
569.5m AUD | 1 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -21 763 099 | |
US |
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 56.4 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 39.8 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 583.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 5.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 8.2 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 6.4 | ||
CH |
Novartis AG
SIX:NOVN
|
180.6B CHF | 5 | ||
CH |
Roche Holding AG
SIX:ROG
|
179.5B CHF | 6.1 | ||
US |
Pfizer Inc
NYSE:PFE
|
158.1B USD | 1.8 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.